VersatileBio develops T4 and T4-like phage biotechnology platforms for medical and biological products. Its T4 Surface Gene‑Protein Display System enables high‑copy display of large proteins (up to 1500 amino acids) on phage capsids, while the T4 Medium Soluble Protein Expression System delivers record‑high soluble protein yields for research and therapeutic use.
Funding
Funding not disclosed
Founders
Product
Problem
Biotech companies often face limitations in producing large, complex proteins at high yields and in delivering protein therapeutics efficiently, leading to high costs and slow development cycles.
Solution
VersatileBio leverages proprietary T4 and T4-like bacteriophage platforms to address these challenges. Its NanoBio system enables high‑density surface display of proteins up to 1,500 amino acids on phage capsids, preserving biological activity for targeted delivery applications. In parallel, the medium‑soluble expression platform delivers record‑breaking soluble protein yields, providing a scalable manufacturing solution for research and therapeutic proteins. By combining surface display and soluble expression technologies, VersatileBio offers a unified platform that accelerates protein development, reduces production costs, and supports the creation of safer, adjuvant‑free vaccine candidates.
Target Audience
Primary customers are biotechnology and pharmaceutical companies that need high‑yield soluble protein production and targeted delivery solutions for therapeutics, vaccines, and research applications.
Features
- T4 surface gene‑protein display system that presents large protein domains (up to 1500 aa) at high copy number on phage capsid exterior
- Medium‑soluble protein expression platform achieving the highest reported soluble protein yields for diverse targets
- Phage‑based delivery vectors that are non‑toxic to humans and inherently immunogenic, enabling adjuvant‑free vaccine designs
- Capability to produce recombinant or subunit vaccines with precise antigen dosing and controlled presentation
- Scalable production process suitable for biotech firms requiring large‑scale protein manufacturing